Global Antibiotics Partner Directory 2021 – Best Deals by Value – ResearchAndMarkets.com


DUBLIN – (COMMERCIAL THREAD)–The “Conditions and agreements of global partnership for antibiotics 2010 to 2021” the report was added to ResearchAndMarkets.com offer.

The Global Antibiotics Partnering Terms and Agreements 2010 to 2021 report provides understanding and access to antibiotics partnership agreements and agreements entered into by the world’s leading healthcare companies.

  • Trends in antibiotics partnership agreements

  • Titles, Advances, Milestones and Royalties Disclosed by Stage of Development

  • Antibiotics partnership contract documents

  • Best Antibiotic Deals By Value

The Global Antibiotics Partnering Terms and Agreements report provides an understanding of and access to the antibiotics agreements and partnership agreements entered into by the world’s leading healthcare companies.

The report provides detailed understanding and analysis of how and why companies are entering into antibiotics partnership agreements. The majority of agreements are in the early stage of development whereby the licensee obtains a right or option right to license the antibiotic technology or product candidates from the licensor. These agreements tend to be multi-component, starting with collaborative R&D and the commercialization of results.

This report details the latest antibiotic deals announced in healthcare sectors, covering:

  • Antibiotics

  • Aminoglycosides

  • Cephalosporin

  • Clindamycin

  • Macrolides

  • Penicillin

  • Quinolones

  • Sulfonamides

  • Tetracycline

Understanding the flexibility of the terms of the agreements negotiated by a potential partner provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of the terms. While many small businesses will be looking for details on payment terms, the devil is in the details of triggering payments – contract documents provide that insight where press releases and databases do not. .

This report contains over 300 links to online copies of antibiotic offerings and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to many questions about a potential partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the agreement.

Contract documents provide the answers to many questions about a potential partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the agreement.

Scope of the report

The 2010-2021 Global Antibiotics Partnership Terms and Agreements are intended to provide the reader with an in-depth understanding and access to the trends and structure of agreements made by leading antibiotics companies around the world.

Global Antibiotics Partnership Terms and Agreements from 2010 to 2021 include:

  • Trends in antibiotics trading in the biopharmaceutical industry since 2010

  • Analysis of the structure of agreements on antibiotics

  • Access to title, advance, milestone and royalty data

  • Access to over 300 antibiotic agreement files and contractual documents, where applicable

  • The leader in antibody sales by value since 2010

  • The most active antibiotics traders since 2010

  • The main partnership resources for antibiotics

In the 2010-2021 Global Antibiotics Partnership Terms and Agreements, the available contracts are listed by:

  • Company from A to Z

  • Title value

  • Stage of development at signing

  • Component type of the agreement

  • Specific therapeutic and technological target

The 2010-2021 Global Antibiotics Partnership Terms and Agreements provide the reader with the following key benefits:

  • In-depth understanding of antibiotic sales trends since 2010

  • Access to title, advance, milestone and royalty data

  • Full access to over 300 antibiotic deals made by the world’s biopharmaceutical companies, as well as sample clauses and real-world contracts where applicable

  • Complete list of antibiotic offers by company from A to Z, value of the operation, phase of development, type of operation and therapeutic orientation

  • Identify the main antibiotic offers by value since 2010

  • Identify the most active antibiotic dealmakers since 2010

  • Detailed access to real antibiotic contracts signed by the twenty-five major pharmaceutical and biotechnology companies

  • Overview of terms included in an antibiotics agreement, plus examples of real-world clauses

  • Understand the key terms of agreements that companies have agreed to in previous agreements

  • Undertake due diligence to assess the adequacy of the terms of your proposed agreement for partner companies

Companies mentioned

  • Oxford Drug Design

  • Gilead Sciences

  • MD Anderson Cancer Center

  • Advanced Biomedical Research and Development Authority

  • Lysando

  • Warp Drive Bio

  • Drug Research and Development Center (CDRD)

  • Vision InSite

  • Directorate General of Armaments of France

  • Q-linea AB

  • Basilea Pharmaceutica

  • European Commission

  • European Union

  • XBiotech

  • QureTech Bio

  • AnnaMed

  • Dr Reddy’s laboratories

  • NovaMedica

  • The Medicines Company

  • Regents of the University of California

  • Paratek Pharmaceuticals

  • Stiefel Laboratories

  • Therapeutic decibel

  • NacuGen Therapeutics

  • Bioresearch Quotient

  • Emerging BioSolutions

  • Novasep

  • Polypeptide Laboratory

  • Premier Inc

  • Optimer Pharmaceutical

  • Auspherix

  • Arcolab strides

  • Synthetic biologics

  • Medimetriks

  • SINTEF

  • Dana-Farber Cancer Institute

  • Finorga

  • Allergan

For more information on this report, visit https://www.researchandmarkets.com/r/de95j1


Comments are closed.